Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0004093 (asthenia)
 2,650 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Efficacy and tolerance of azelastine (A 5610; CAS 58581-89-8), a new antiallergic compound with a unique structure, were investigated over up to one year of treatment in 225 male and female out-patients (age mean +/- s = 48 +/- 13 years) suffering from chronified intrinsic asthma. The trial was conducted by 24 German and Austrian consulting physicians of pneumology. Plasma levels indicated sufficient compliance in almost 90% of the patients. Tablets containing 4.4 mg azelastine HCl were administered b.i.d. in addition to the pre-existing antiasthmatic medication. Only other antiallergic agents were excluded. Adverse events, vital parameters and laboratory tests on safety were tightly assessed. Eighteen patients dropped out because of adverse events, 78 reported adverse experiences under therapy, normally mild and "vegetative" symptoms. No indicative findings regarding blood pressure, heart rate and laboratory tests were seen. The most frequent observations were taste disorders, asthenia and weight gain. No serious side effects at all were reported. The results on efficacy obtained from this non-controlled study may be predicative due to a baseline validation by an initial single blind placebo controlled run-in phase. Statistically significant improvements were seen for FEV1 and for the physicians' and the patients' rating on efficacy. To a lesser extent peak flow and airway resistance were improved, too. Thus, azelastine was safely tolerated over one year and might be effective in intrinsic asthma.
 ...
PMID:Long-term multicentric study with azelastine in patients with intrinsic asthma. 208 34

Although citrulline malate (CM; CAS 54940-97-5, Stimol) is used against fatigue states, its anti-asthenic effect remains poorly documented. The objective of this double-blind study was to evaluate the effect of oral ingestion of CM on a rat model of asthenia, using in situ (31)Phosphorus magnetic resonance spectroscopy ((31)P-MRS). Muscle weakness was induced by intraperitoneal injections of Klebsiella pneumoniae endotoxin (lipopolysaccharides at 3 mg/kg) at t(0) and t(0)+24 h. For each animal, muscle function was investigated strictly non-invasively before (t(0)-24 h) and during (t(0)+48 h) endotoxemia, through a standardized rest-stimulation-recovery protocol. The transcutaneous electrical stimulation protocol consisted of 5.7 min of repeated isometric contractions at a frequency of 3.3 Hz, and force production was measured with an ergometer. CM supplementation in endotoxemic animals prevented the basal phosphocreatine/ATP ratio reduction and normalized the intracellular pH (pH(i)) time-course during muscular activity as a sign of an effect at the muscle energetics level. In addition, CM treatment avoided the endotoxemia-induced decline in developed force. These results demonstrate the efficiency of CM for limiting skeletal muscle dysfunction in rats treated with bacterial endotoxin.
 ...
PMID:Beneficial effects of citrulline malate on skeletal muscle function in endotoxemic rat. 1903 44